KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Share-based Compensation (2016 - 2025)

Vertex Pharmaceuticals has reported Share-based Compensation over the past 17 years, most recently at $157.6 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $157.6 million for Q4 2025, down 6.08% from a year ago — trailing twelve months through Dec 2025 was $685.9 million (down 1.8% YoY), and the annual figure for FY2025 was $685.9 million, down 1.8%.
  • Share-based Compensation for Q4 2025 was $157.6 million at Vertex Pharmaceuticals, down from $194.9 million in the prior quarter.
  • Over the last five years, Share-based Compensation for VRTX hit a ceiling of $208.6 million in Q4 2023 and a floor of $103.0 million in Q3 2021.
  • Median Share-based Compensation over the past 5 years was $133.2 million (2022), compared with a mean of $144.9 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 87.09% in 2023 and later decreased 19.56% in 2024.
  • Vertex Pharmaceuticals' Share-based Compensation stood at $118.6 million in 2021, then fell by 5.99% to $111.5 million in 2022, then soared by 87.09% to $208.6 million in 2023, then fell by 19.56% to $167.8 million in 2024, then dropped by 6.08% to $157.6 million in 2025.
  • The last three reported values for Share-based Compensation were $157.6 million (Q4 2025), $194.9 million (Q3 2025), and $167.3 million (Q2 2025) per Business Quant data.